One in Four: An Anonymized Case Study in Plasma Center Site Selection

By Aurea Vita Advisors (AVA)  |  4 min read

Most plasma collection centers don't fail in the boardroom. They fail on a lease — in a floorplan that can't support donor throughput, a demographic band with the wrong income profile (which would include profiles related to: university students, military personnel, under-employed professionals, retired individuals, etc.), a location a few critical minutes off the daily route donors already drive.

This case study looks at one operator who avoided that outcome: an independent plasma collection operator preparing to launch in a competitive South Florida-USA submarket brought Aurea Vita Advisors (AVA) in to evaluate a shortlist of candidate real estate sites before a single lease was signed.

AVA provided the site selection strategy and comparative evaluation behind that decision. Details identifying the operator and the specific properties involved have been withheld at the client's request; the facts of the engagement have not been altered.

At a Glance

•        Facility type: Independent plasma collection center, pre-lease launch stage

•        Market: Competitive South Florida submarket with multiple established fractionator-operated centers already active

•        Engagement: Site selection strategy, comparative real estate due diligence, donor-demographic and competitive analysis, launch-site recommendation

•        Result: One candidate site advanced to the Letter of Intent stage; the remaining candidates were rejected or deprioritized before capital was committed

•        Current status: Client advancing toward LOI execution on the recommended site; additional submarkets under evaluation to support a multi-center pipeline

The Situation

Plasma collection is, underneath the regulatory framework, somewhat of a retail traffic business. Back-of-house operations — sample testing, cold-chain storage, quality systems — run on pharmaceutical-manufacturing discipline. Front-of-house donor acquisition runs loosely on retail principles: donors are walk-ins, not largely referrals; and they rarely travel far from home or work to donate. That makes the real estate decision the single highest-leverage commercial call an operator makes before a center ever opens — not a facilities afterthought.

This operator had a shortlist of candidate properties and needed a structured, outside evaluation before committing capital to any one of them — not a gut check, and not a rubber stamp on whichever site had already generated internal enthusiasm.

The Engagement

AVA's evaluation applied the same comparative framework used across its site selection engagements, adapted to the local competitive landscape. That included:

•        Mapping each candidate against donor-demographic criteria — population density and household income bands calibrated to the segment that actually donates or has the real possibility of donating plasma

•        Assessing retail co-location dynamics: proximity to the kind of high-traffic consumer anchors that generate organic, repeat foot traffic rather than one-time visits

•        Competitive mapping against existing fractionator-operated centers already active in the market

•        Physical and structural due diligence — floorplan usability, parking and freight access, zoning and permitting exposure, probability of satisfying FDA and EMA requirements, and other site-level risk factors that don't show up on a broker flyer

•        Scoring each candidate on a consistent, weighted basis so the comparison held up independent of which site “felt” right

Industry experience suggests operators typically need to evaluate roughly ten candidate properties for every one that reaches a signed lease. This engagement worked from a shorter, client-sourced list, which raised the stakes on getting the comparative scoring right rather than defaulting to the most available option.

The Result

Of the candidate sites evaluated, one was identified as a clear primary target. The remaining candidates were rejected or flagged as high-risk for reasons that ranged from household-income bands well outside the donor target window, to the absence of a strong-enough retail traffic anchor, to structural and access limitations, to nearby land uses that raised both optics and staff-safety concerns.

The recommended site combined the traits the framework is built to identify: a functional single-story footprint, income demographics inside the target collection band, direct adjacency to a high-traffic retail anchor, and a workable distance from existing competitor locations.

“We had a short list and strong opinions about which site we liked,” said the project’s capital-backer.  “AVA's process is what kept us from signing a lease on the wrong one.”

“Site selection is where most of the capital risk in this industry actually sits because of the downstream implications,” added Chris Barber, Principal of Aurea Vita Advisors. “Get the real estate wrong and no amount of operational-execution excellence fixes it later.”

What's Next

The engagement is moving from recommendation to execution: the client is taking steps toward advancing on lease terms on the recommended site, with zoning verification and test-fit planning soon after. AVA and the client are also discussing an expanded site search into additional Florida submarkets, to build a pipeline that supports a multi-center strategy rather than a single-location launch.

“A site can look right on a broker's flyer and still be wrong for this business,” remarked Charles Auger, Principal of Aurea Vita Advisors. “The value we bring is filtering that out before it becomes a 10–20-year lease.”

Why It Matters for Other Operators

Rejecting three out of four candidate sites is not a failure rate — it's the discipline working as intended. The real estate decision behind a plasma collection center gets made once, gets locked in for years, and is nearly impossible to unwind once a lease is signed. For operators evaluating a launch, an acquisition, or an expansion, the relevant question isn't whether a site is available. It's whether someone has actually stress-tested it against the demographic, competitive, and operational factors that determine whether it hits a sustainable cost per liter — before the ink dries.

Work With AVA

AVA provides site selection strategy, real estate due diligence, regulatory strategy, and plasma center operations management to operators and fractionators. If you're evaluating a build-out, an acquisition, or an expansion, engage with Aurea Vita Advisors before you sign anything.

About Aurea Vita Advisors

Aurea Vita Advisors (AVA) is the only credible consulting firm specializing in international human blood plasma collection led by former plasma collection executives. Founded by industry veterans Charles Auger and Chris Barber, the firm brings a combined 74 years of hands-on plasma industry experience to site selection, regulatory strategy, M&A due diligence, fleet infrastructure build-out, and operations management for plasma collection centers and fractionators worldwide. AVA's advisors have launched 82 centers organically and integrated 78 more through M&A, with engagements spanning five countries and three continents. For more information, visit AureaVitaAdvisors.com.

Tags: Plasma Collection, Site Selection, Real Estate Due Diligence, Donor Demographics, Competitive Analysis, Plasma Center Consultant, Cost Per Liter, Case Study, Plasma Center Operations, Market Entry Strategy